Results 161 to 170 of about 4,135 (194)

Epigenetic Signatures of Social Defeat Stress Varying Duration. [PDF]

Int J Mol Sci
Bondar N, Reshetnikov V, Ritter P, Ershov N, Zhukova N, Kolmykov S, Merkulova T.   +6 more
europepmc   +1 more source

Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility

, 2014
Robert M. Rzasa, Michael Frohn, Kristin L. Andrews, Samer Chmait, Ning Chen, Jeffrey Clarine, Carl D. Davis, Heather Eastwood, Daniel B. Horne, Essa Hu, Adrie Jones, Matthew R. Kaller, Roxanne K. Kunz, Silke Miller, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Amy C. Porter, Andreas Reichelt, Xiaoning Zhao, James Treanor, Jennifer R. Allen   +21 more
openalex   +2 more sources

Phosphodiesterase 10A Inhibitor Modulates Right Ventricular Outflow Tract Electrophysiological Activities and Calcium Homeostasis via the cGMP/PKG Pathway. [PDF]

J Cell Mol Med
Lin FZ, Chen YC, Yang HY, Lin WS, Lu YY.
europepmc   +1 more source

The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia

, 2011
Ginny D. Ho, Shu‐Wei Yang, Jennifer Smotryski, Ana Bercovici, Terry L. Nechuta, Elizabeth M. Smith, William T. McElroy, Zheng Tan, Deen Tulshian, Brian A. McKittrick, William J. Greenlee, Alan Hruza, Xiao Li, Diane Rindgen, Deborra Mullins, M. Guzzi, Xiaoping Zhang, Carina Bleickardt, Robert A. Hodgson   +18 more
openalex   +1 more source

Isolated Pancerebellar Syndrome With anti-GQ1b IgG Positivity: A Case Report. [PDF]

Neurohospitalist
Daghlas I, Solovey L, Douglas VC.
europepmc   +1 more source

Synthesis and in vitro biological evaluation of pyrazole group-containing analogues for PDE10A

, 2012
Junfeng Li, Hongjun Jin, Haiying Zhou, Justin M. Rothfuss, Zhude Tu   +4 more
openalex   +2 more sources

In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia. [PDF]

Clin Psychopharmacol Neurosci
Barbagallo F, Assenza MR, Messina A.
europepmc   +1 more source

A strategy to improve the success rate of CNS drug development: TAK-063, a novel PDE10A inhibitor, as a case study

, 2017
Haruhide Kimura
openalex   +2 more sources

DAGLA autoantibody experience at Mayo Clinic. [PDF]

J Neurol
Vorasoot N, Isitan-Alkawadri C, Pillai B, Miske R, Dubey D, Gilligan M, Hahn S, Mills J, Pittock SJ, Zekeridou A, McKeon A.   +10 more
europepmc   +1 more source

Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket

, 2016
Masato Yoshikawa, Takenori Hitaka, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo, Hironori Kokubo, Hideyuki Oki, Kosuke Nakashima, Takahiko Taniguchi   +8 more
openalex   +1 more source